Prudential Financial Inc. Sells 200 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Prudential Financial Inc. lessened its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,040 shares of the specialty pharmaceutical company’s stock after selling 200 shares during the period. Prudential Financial Inc. owned approximately 0.08% of ANI Pharmaceuticals worth $942,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. State Street Corp grew its holdings in shares of ANI Pharmaceuticals by 9.1% in the third quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company’s stock worth $41,991,000 after acquiring an additional 58,698 shares during the period. Global Alpha Capital Management Ltd. grew its stake in shares of ANI Pharmaceuticals by 16.4% during the 4th quarter. Global Alpha Capital Management Ltd. now owns 624,550 shares of the specialty pharmaceutical company’s stock valued at $34,525,000 after purchasing an additional 88,100 shares during the period. JPMorgan Chase & Co. increased its position in shares of ANI Pharmaceuticals by 159.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock valued at $33,101,000 after purchasing an additional 340,854 shares during the last quarter. William Blair Investment Management LLC lifted its stake in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. William Blair Investment Management LLC now owns 485,268 shares of the specialty pharmaceutical company’s stock worth $26,826,000 after purchasing an additional 10,440 shares during the period. Finally, Geode Capital Management LLC grew its position in ANI Pharmaceuticals by 4.2% during the third quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock valued at $25,373,000 after buying an additional 17,314 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They set a “buy” rating and a $80.00 price target on the stock. StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 14th. JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an “overweight” rating and a $85.00 price objective on the stock. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $79.75.

Insider Buying and Selling

In other news, SVP Krista Davis sold 1,000 shares of the company’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total transaction of $60,860.00. Following the sale, the senior vice president now directly owns 66,525 shares in the company, valued at approximately $4,048,711.50. This represents a 1.48 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the transaction, the vice president now owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,200 shares of company stock worth $191,776. Corporate insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Stock Down 0.8 %

ANIP opened at $66.99 on Tuesday. The company has a market capitalization of $1.46 billion, a PE ratio of -121.80 and a beta of 0.49. The firm has a 50-day simple moving average of $61.58 and a two-hundred day simple moving average of $58.81. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $70.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.